Understanding the distinct contributions of canonical and non-canonical NF-κB activation in neutrophils, and their implications for breast cancer, is critical for developing therapeutic strategies aimed at modulating immune responses in the TME[76]. Here, NFKB1 is linked to breast carcinoma.